FOR IMMEDIATE RELEASE
VESTECK, Inc.
West Chester, PA (July 1, 2022) – VESTECK, Inc. Expands the Scientific Advisory Board to include an international luminary in complex aortic repair, Dr. Sukgu Han.
VESTECK is pleased to announce that Dr. Sukgu Han has graciously agreed to join the VESTECK Scientific Advisory Board.
Dr. Han is the Co-Director of the Comprehensive Aortic Center at Keck Hospital of the University of Southern California. Dr. Han is also an Associate Professor of Surgery in the Division of Vascular Surgery and Endovascular Therapy at Keck School of Medicine of USC.
“I am excited to join the VESTECK Scientific Advisory Board, commented Dr. Han. The VESTECK SUTURE-TIGHTTM catheter technology will bring a valuable resource to physicians addressing complex aortic disease.”
VESTECK CEO, Joe Rafferty said, “we are extremely fortunate and excited to welcome Dr. Han to the VESTECK SAB team. We look forward to his valuable insight, progressing the “SUTURE-TIGHTTM” catheter technology,”
Dr. Han completed his medical school at UC Irvine. During his surgical residency at USC, Dr. Han also obtained his master’s degree in Biomedical Engineering. He completed his vascular surgery fellowship at UCSF and obtained additional training in complex aortic repairs at the Mayo Clinic, Rochester, MN.
The VESTECK Suture-Tight catheter secures endovascular aortic repair grafts to the aorta at the time of initial implant or during repair procedures.
About Vesteck Inc.:
VESTECK, Inc. (WWW.VESTECK.com) is an early-stage medical device company focused on bringing their proprietary technology to the aortic repair and structural heart markets. The first product, the “SUTURE-TIGHTTM” nitinol suture delivery catheter will bring a novel technology to the endovascular aortic repair market, solving a significant global challenge.
VESTECK is represented by Kevin M. Granahan of Fox Rothschild LLP
MEDIA CONTACTS: VESTECK, Inc. CEO, Joe Rafferty, J.Rafferty@VESTECK.com 610-457-7324
FOR IMMEDIATE RELEASE
VESTECK, Inc. Delivers multiple presentations at Charring Cross International Symposium
West Chester, PA (May 10, 2022) – VESTECK, Inc. is pleased to announce their participation and strong podium presence at the Charring Cross International Vascular Symposium.
“Charring Cross” (CX), held annually in London, UK, is considered one of the premier global Vascular/Endovascular symposiums. Key Opinion Leaders from around the world assemble to candidly discuss the most recent breakthroughs and controversies. CX attendees spent an entire day discussing solutions to the current challenges with the durability of endovascular aortic repair grafts (EVAR/TEVAR).
VESTECK SAB member Dr. David H. Deaton gave a presentation during the “Innovation Session” on the problems with endografting and the benefits the VESTECK SUTURE-TIGHT suture delivery catheter will bring. Dr. Deaton’s presentation stimulated several questions from the audience. The follow-on discussion was very encouraging relative to the benefits the SUTURE-TIGHT catheter brings to patients, physicians and payors.
The newest member of the VESTECK Scientific Advisory Board, Dr. Dai Yamanouchi, gave two presentations at CX. A Vascular Surgeon, Dr. Yamanouchi is an Associate Professor at the University of Wisconsin School of Medicine.
VESTECK CEO, Joe Rafferty also presented the SUTURE-TIGHT technology in the “Innovation Session’s Dragon’s Den,” a “Shark Tank” type environment for novel endovascular technology. The judges had fantastic feedback on how VESTECK answers a significant unmet need in EVAR.
The VESTECK Suture-Tight catheter secures endovascular grafts to the aorta at the time of initial implant or during repair procedures.
About Vesteck Inc.:
VESTECK, Inc. (WWW.VESTECK.com) is an early-stage medical device company focused on bringing their proprietary technology to the aortic repair and structural heart markets. Their first product, the “Suture-Tight” nitinol suture delivery catheter will bring a novel technology to endovascular aortic repair market solving a significant global challenge for physicians, patients and payors.
VESTECK is represented by Kevin M. Granahan of Fox Rothschild LLP
MEDIA CONTACTS: VESTECK, Inc. CEO, Joe Rafferty, J.Rafferty@VESTECK.com 610-457-7324
FOR IMMEDIATE RELEASE
VESTECK, Inc.
West Chester, PA (July 26, 2022) – VESTECK, Inc. is pleased to announce that, international thought leader, Professor Andrew Holden has graciously agreed to join the VESTECK Scientific Advisory Board (SAB).
A New Zealander, Professor Holden is currently the Director of Northern Region Interventional Radiology Service and is based at Auckland City Hospital. As well, he is Professor of Radiology at the University of Auckland and Co-Director of the Auckland Endovascular Service.
Professor Holden is known worldwide as an educator, clinician and the author of over 100 peer reviewed articles. He has been involved in over 75 medical device trials and is a frequent Principal Investigator, personally performing many “first in human” procedures.
“The VESTECK SUTURE-TIGHTTM catheter appears to be very straightforward, the right technology at the right time,” said Dr. Holden. “Around the world, approximately 80% of all Aortic Abdominal Aneurysm patients needing repairs, receive an endovascular repair (EVAR). The “SUTURE-TIGHT”TM catheter, fixes the EVAR graft to the aorta. This should significantly reduce the number of patients returning for complex repair procedures and eliminate their associated procedural costs.”
In 2018 Dr. Holden was recognized for his contributions to vascular and endovascular intervention, being awarded an Officer of the New Zealand Order of Merit medal.
We are humbled that Dr. Holden thinks so highly of the VESTECK technology and team to join the Scientific Advisory Board, commented VESTECK CEO Joe Rafferty. “Professor Holden is respected around the world as a skilled interventionalist and critical thinker. He will absolutely challenge us to bring the finest technology for physicians and patients.”
The VESTECK “SUTURE-TIGHT”TM catheter secures endovascular aortic repair grafts to the aorta at the time of initial implant or during repair procedures. VESTECK is in preparation for a 100-patient clinical trial.
About Vesteck Inc.:
VESTECK, Inc. (WWW.VESTECK.com) is an early-stage medical device company focused on bringing their platform technology to the aortic repair and structural heart markets. The first product, the “SUTURE-TIGHT”TM nitinol suture delivery catheter secures endovascular grafts to the aorta at the time of initial implant or during complex and expensive repair procedures.
VESTECK is represented by Kevin M. Granahan of Fox Rothschild LLP
MEDIA CONTACTS: VESTECK, Inc. CEO, Joe Rafferty, J.Rafferty@VESTECK.com 610-457-7324